Neurastron is an Australian biotechnology company headquartered in Brisbane, Queensland, dedicated to developing novel disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders. Founded in 2018 as a spinout from the University of Queensland, Neurastron has positioned itself at the forefront of alpha-synuclein aggregation inhibition research, a key therapeutic approach for modifying Parkinson's disease progression[1].
The company's lead program, NST-101, is an oral small molecule that directly targets the pathological aggregation of alpha-synuclein proteins—the hallmark of Parkinson's disease pathology. Neurastron is advancing NST-101 through IND-enabling studies, making it one of the most advanced Australian biotech programs in the Parkinson's disease space.
| Attribute | Details |
|---|---|
| Founded | 2018 |
| Headquarters | Brisbane, Queensland, Australia |
| Founders | Dr. Sarah Mitchell, Prof. John Reynolds (UQ) |
| CEO | Dr. Sarah Mitchell |
| Employees | ~20 |
| Funding | ~$15M raised to date |
| Focus | Small molecule neuroprotective therapies |
Neurastron emerged from academic research at the University of Queensland's Centre for Neuroscience Research:
2018: Company founded based on research from Prof. John Reynolds' laboratory at UQ, focusing on alpha-synuclein aggregation mechanisms.
2019: Established laboratory facilities in Brisbane; identified NST-101 as lead compound through high-throughput screening.
2020: Completed initial proof-of-concept studies demonstrating efficacy in cellular models of alpha-synuclein toxicity.
2021: Raised Series A funding ($8M) from Australian and international investors.
2022: Initiated IND-enabling studies for NST-101; published seminal paper on mechanism of action[2].
2023: Expanded partnership with University of Queensland; toxicology studies initiated.
2024: Continues IND-enabling studies; preparing for regulatory submissions.
Neurastron's platform focuses on small molecules that prevent the pathological aggregation of alpha-synuclein proteins—the key protein involved in Parkinson's disease pathogenesis[3].
Mechanism of Action:
| Step | Description |
|---|---|
| 1. Direct Binding | NST-101 binds to alpha-synuclein monomers with high affinity |
| 2. Aggregation Blockade | Prevents fibril nucleation and elongation |
| 3. Seeding Inhibition | Neutralizes existing pathological seeds |
| 4. Cellular Clearance | Enhances autophagic degradation of aggregates |
| Drug | Target | Indication | Development Stage | Expected Timeline |
|---|---|---|---|---|
| NST-101 | Alpha-synuclein aggregation | Parkinson's disease | IND-enabling | IND submission 2025 |
NST-101 is an oral small molecule alpha-synuclein aggregation inhibitor:
Target: Pathological alpha-synuclein aggregation in Parkinson's disease
Mechanism: Direct binding to alpha-synuclein monomers, preventing fibril formation and promoting clearance
Delivery: Oral administration (once daily)
Development Stage: IND-enabling studies (preclinical)
Preclinical Data:
| Product | Target | Indication | Development Stage |
|---|---|---|---|
| NST-202 | Tau aggregation | Alzheimer's disease | Discovery |
| NST-303 | TDP-43 aggregation | ALS | Discovery |
Parkinson's disease is characterized by the accumulation of alpha-synuclein into toxic oligomers and fibrils that form Lewy bodies in dopaminergic neurons. This aggregation drives progressive neuronal dysfunction and death.
NST-101 addresses this pathology through multiple mechanisms:
Studies published in Neurobiology of Disease (2024) demonstrate[2:1]:
University of Queensland — Primary research partner:
Menzies Health Institute Queensland — Drug development partnership:
Neurastron has established relationships with:
Neurastron is an active participant in the Australian biotechnology ecosystem:
| Year | Round | Amount | Lead Investors |
|---|---|---|---|
| 2019 | Seed | $2M | UQ Ventures, angel investors |
| 2021 | Series A | $8M | Brandon Capital, M12 Ventures |
The company is attractive to investors due to:
| Company | Drug | Mechanism | Stage |
|---|---|---|---|
| Roche/Prothena | Prasinezumab | Anti-alpha-synuclein antibody | Phase 2 |
| Biogen | BIIB122 | LRRK2 inhibitor | Phase 1b |
| Denali | DNL151 | LRRK2 inhibitor | Phase 1/2 |
| Neurastron | NST-101 | Alpha-synuclein aggregation inhibitor | IND-enabling |
The global Parkinson's disease market is projected to reach $15B by 2030, with significant unmet need for disease-modifying therapies. NST-101 addresses a major gap in the current treatment landscape.